Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

NEOadjuvant Abemaciclib and GIredestrant TriaL in Patients with ER-positive, HER2-negative Early Breast Cancer

NCT06259929 is registered in ClinicalTrials.gov with Fondazione Oncotech as lead sponsor.

NCT NCT06259929
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06259929 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
NEOadjuvant Abemaciclib and GIredestrant TriaL in Patients with ER-positive, HER2-negative Early Breast Cancer
Lead sponsor
Fondazione Oncotech
Phase
Phase 2
Overall status
Recruiting
Start date
January 27, 2025
Completion date
April 1, 2027
Enrollment
51 (estimated)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer